Manufacturers Increase Drug Prices Twice as Fast During Drug Shortages
Prices of prescription drugs in short supply between 2015 and 2016 were found to increase more than twice as quickly as they would have in the absence of a shortage.
Treatments
Generic Medications Offer Savings vs Brand-Name Combination Treatments
The difference in spending by Medicare on brand-name combination medications and the cost of the equivalent generic constituents was an estimated $925 million for 2016.
In the Wake of Charlie Gard, Who Decides the Best Interests of Critically Ill Children?
The use of specialist services may allow more equitable solutions to treatment questions in critically ill children as they are less formal and adversarial than the courts.
Does Right to Try Legislation Improve on Existing Compassionate Use Programs?
While politicians celebrate the passage of the Right to Try Act, physicians must closely monitor the outcomes to mitigate the potential consequences of this law.
Improving Evidence-Based Clinical Decision Making Through Education
“Irrational” treatment decisions are sometimes made based on rewards, risk, and potential therapeutic trade-offs.
FDA: Lutathera Approved to Treat Gastroenteropancreatic Neuroendocrine Tumors
The radioactive drug is approved to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Liquid Vancomycin Approved by FDA for C diff Diarrhea, S aureus Enterocolitis
The oral solution will replace a compounding kit used to prepare vancomycin oral liquid therapy.
FDA Approves Mavyret for Treatment of Hepatitis C
Mavyret has been approved by the FDA to treat adults with certain types of chronic hepatitis C virus.
NSAID Use and Myocardial Infarctions — A Deadly Pain Reliever?
As physicians, it may be more prudent to recommend physical therapy for pain relief whenever possible and to suggest exploring alternative therapeutic modalities.
Hepatitis C Treatment Shows Impressive Results With New Three-Drug Combo Pill
Sofosbuvir, velpatasvir and voxilaprevir are used for patients who have failed with direct-acting antivirals.
